NCT02038049View on ClinicalTrials.gov

A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 20, 2013

Primary Completion Date

May 5, 2015

Study Completion Date

September 13, 2018

Conditions
Relapse Remitting Multiple Sclerosis
Interventions
DRUG

VAY736

Single intravenous infusion of VAY736 (10 mg/kg)

DRUG

Placebo

Placebo to VAY736

Trial Locations (5)

61068

Novartis Investigative Site, Kharkiv

79010

Novartis Investigative Site, Lviv

90806

Novartis Investigative Site, Long Beach

92103

Novartis Investigative Site, San Diego

501 03

Novartis Investigative Site, Hradec Králové

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY